Diego DAgostino
Overview
Explore the profile of Diego DAgostino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nolan T, Santolaya M, De Looze F, Marshall H, Richmond P, Henein S, et al.
Vaccine
. 2019 Jan;
37(9):1209-1218.
PMID: 30691980
Background: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults...
2.
Martinon-Torres F, Bernatowska E, Shcherbina A, Esposito S, Szenborn L, Campins Marti M, et al.
Pediatrics
. 2018 Aug;
142(3).
PMID: 30068713
Background: The capsular group B meningococcal vaccine (4CMenB) is recommended for children with complement deficiencies, asplenia, and splenic dysfunction; however, data on the immunogenicity of 4CMenB in these "at-risk" children...
3.
Szenborn L, Block S, Jackowska T, Konior R, DAgostino D, Smolenov I, et al.
Pediatr Infect Dis J
. 2018 Jan;
37(5):475-482.
PMID: 29329168
Background: Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis...
4.
Bona G, Castiglia P, Zoppi G, de Martino M, Tasciotti A, DAgostino D, et al.
Vaccine
. 2016 May;
34(29):3363-70.
PMID: 27181507
Background: MenACWY-CRM (Menveo(®); GlaxoSmithKline) and MenACWY-TT (Nimenrix(®); Pfizer) are two meningococcal vaccines licensed in the European Union for use in both children and adults. While both vaccines target meningococcal serogroups...
5.
McQuaid F, Snape M, John T, Kelly S, Robinson H, Yu L, et al.
CMAJ
. 2015 Mar;
187(7):E215-E223.
PMID: 25802309
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18-20...
6.
Block S, Szenborn L, Daly W, Jackowska T, DAgostino D, Han L, et al.
Vaccine
. 2015 Mar;
33(21):2500-10.
PMID: 25795256
Background: A meningococcal vaccine protective against all major disease-associated serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer-blinded, randomized, controlled study,...
7.
La Mura V, De Renzo A, Perna F, DAgostino D, Masarone M, Romano M, et al.
J Hepatol
. 2008 Aug;
49(4):557-63.
PMID: 18678434
Background/aims: Prevalence of HCV infection in non-Hodgkin's lymphoma is high. The impact of antiviral therapy on the natural history of this subgroup of lymphomas after a successful chemotherapy regimen is...
8.
Cancello G, Montagna E, DAgostino D, Giuliano M, Giordano A, Di Lorenzo G, et al.
Breast Cancer Res
. 2008 Jul;
10(4):R60.
PMID: 18631394
Introduction: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy...
9.
De Laurentiis M, Cancello G, DAgostino D, Giuliano M, Giordano A, Montagna E, et al.
J Clin Oncol
. 2008 Jan;
26(1):44-53.
PMID: 18165639
Purpose: We conducted a meta-analysis of randomized trials that evaluated the efficacy of incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC). We aimed to determine whether this approach...
10.
Picardi M, Ciancia R, De Renzo A, Montante B, Ciancia G, Zeppa P, et al.
Haematologica
. 2006 Jul;
91(7):960-3.
PMID: 16818285
The accuracy of standard methods in estimating bulky lesions requires validation. We used clinical/computed tomography (CT) evaluation and power Doppler ultrasound (US) to detect bulky disease in 137 consecutive Hodgkin's...